Debbie L. Cohen

Debbie L. Cohen

Auto-generated profile, based on publicly available information

Debbie L. Cohen

Renal-Electrolyte and Hypertension Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 December 2020 in Annals of Internal Medicine
Verified
Journal Article
Closed access
JCJordana B. Cohen
Jordana B. Cohen
DCDebbie L. Cohen
Debbie L. Cohen
DHDaniel S. Herman
Daniel S. Herman
JLJohn Leppert
John Leppert
JBJames Brian Byrd
James Brian Byrd
VBVivek Bhalla
Vivek Bhalla
Primary aldosteronism is a common cause of treatment-resistant hypertension, but evidence suggests low rates of testing for primary aldosteronism. The authors used Veterans Health Administration da... Visual Testing for Primary Aldosteronism in U.S. Veterans Primary aldosteronism is a common cause of treatment-resistant hypertension, but evidence suggests low rates of testing for primar... Background: Primary aldosteronism is a common cause of treatment-resistant hypertension. However, evidence from local health systems suggests low rates of testing for primary aldosteronism. Objecti...

1 January 2021 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
PDF file
KFKevin S. Fay
Kevin S. Fay
DCDebbie L. Cohen
Debbie L. Cohen

1 January 2011 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
DCDebbie L. Cohen
Debbie L. Cohen
LBLeAnne T. Bloedon
LeAnne T. Bloedon
RRRand L. Rothman
Rand L. Rothman
JFJohn T. Farrar
John T. Farrar
MGMary Lou Galantino
Mary Lou Galantino
RTRaymond R. Townsend
Raymond R. Townsend
The prevalence of prehypertension and Stage 1 hypertension continues to increase despite being amenable to non‐pharmacologic interventions. Iyengar yoga (IY) has been purported to reduce blood pressure (BP) though evidence from randomized trials is lacking. We conducted a randomized controlled trial to assess the effects of 12 weeks of IY versus enhanced usual care (EUC) (based on individual dietary adjustment) on 24‐h ambulatory BP in yoga‐naïve adults with untreated prehypertension or Stage 1 hypertension. In total, 26 and 31 subjects in the IY and EUC arms, respectively, completed the study. There were no differences in BP between the groups at 6 and 12 weeks. In the EUC group, 24‐h systolic BP (SBP), diastolic BP (DBP) and mean arterial pressure (MAP) significantly decreased by 5, 3 and 3 mmHg, respectively, from baseline at 6 weeks (P < .05), but were no longer significant at 12 weeks. In the IY group, 24 h SBP was reduced by 6 mmHg at 12 weeks compared to baseline (P = .05). 24 h DBP (P < .01) and MAP (P < .05) decreased significantly each by 5 mmHg. No differences were observed in catecholamine or cortisol metabolism to explain the decrease in BP in the IY group at 12 weeks. Twelve weeks of IY produces clinically meaningful improvements in 24 h SBP and DBP. Larger studies are needed to establish the long term efficacy, acceptability, utility and potential mechanisms of IY to control BP.

15 March 2013 in The Journal of Clinical Hypertension
Verified
Journal Article
Open access
PDF file
LFLauren Fishbein
Lauren Fishbein
RORobert Orlowski
Robert Orlowski
DCDebbie Cohen
Debbie Cohen
Pheochromocytomas and paragangliomas are rare tumors with high morbidity rates caused by excessive catecholamine secretion, even though the majority of tumors are benign. The use of perioperative blockade regimens, together with improved surgical techniques, has greatly impacted the perioperative morbidity associated with these tumors. The old dogma of the “tumor of tens” no longer holds true. For example, at least one third of all pheochromocytomas and paragangliomas are hereditary, with mutations in 1 of 10 well‐characterized susceptibility genes, and one quarter of all tumors are malignant. This review focuses on the perioperative management of pheochromocytoma and paragangliomas and the clinical implications of the associated genetic mutations.

28 January 2016 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
MTManjula Kurella Tamura
Manjula Kurella Tamura
EVEric Vittinghoff
Eric Vittinghoff
JYJingrong Yang
Jingrong Yang
AGAlan S. Go
Alan S. Go
SSStephen L. Seliger
Stephen L. Seliger
KYKristine Yaffe
Kristine Yaffe
Anemia is common among patients with chronic kidney disease (CKD) but its health consequences are poorly defined. The aim of this study was to determine the relationship between anemia and cognitive decline in older adults with CKD. We studied a subgroup of 762 adults age ≥55 years with CKD participating in the Chronic Renal Insufficiency Cohort (CRIC) study. Anemia was defined according to the World Health Organization criteria (hemoglobin <13 g/dL for men and <12 g/dL for women). Cognitive function was assessed annually with a battery of six tests. We used logistic regression to determine the association between anemia and baseline cognitive impairment on each test, defined as a cognitive score more than one standard deviation from the mean, and mixed effects models to determine the relation between anemia and change in cognitive function during follow-up after adjustment for demographic and clinical characteristics. Of 762 participants with mean estimated glomerular filtration rate of 42.7 ± 16.4 ml/min/1.73 m2, 349 (46 %) had anemia. Anemia was not independently associated with baseline cognitive impairment on any test after adjustment for demographic and clinical characteristics. Over a median 2.9 (IQR 2.6–3.0) years of follow-up, there was no independent association between anemia and change in cognitive function on any of the six cognitive tests. Among older adults with CKD, anemia was not independently associated with baseline cognitive function or decline.

1 March 2024 in Hypertension
Verified
Journal Article
Closed access
ATAdina F. Turcu
Adina F. Turcu
YTYuta Tezuka
Yuta Tezuka
JLJung Soo Lim
Jung Soo Lim
ZSZara Salman
Zara Salman
KSKartik Sehgal
Kartik Sehgal
WRWilliam E. Rainey
William E. Rainey
BACKGROUND: Primary aldosteronism (PA) has been broadly dichotomized into unilateral and bilateral forms. Adrenal vein sampling (AVS) lateralization indices (LI) ≥2 to 4 are the standard-of-care to recommend unilateral adrenalectomy for presumed unilateral PA. We aimed to assess the rates and characteristics of residual PA after AVS-guided adrenalectomy. METHODS: We conducted an international, retrospective, cohort study of patients with PA from 7 referral centers who underwent unilateral adrenalectomy based on LI≥4 on baseline and/or cosyntropin-stimulated AVS. Aldosterone synthase (CYP11B2) immunohistochemistry and next generation sequencing were performed on available formalin-fixed paraffin-embedded adrenal tissue. RESULTS: The cohort included 283 patients who underwent AVS-guided adrenalectomy, followed for a median of 326 days postoperatively. Lack of PA cure was observed in 16% of consecutive patients, and in 22 patients with lateralized PA on both baseline and cosyntropin-stimulated AVS. Among patients with residual PA postoperatively, 73% had multiple CYP11B2 positive areas within the resected adrenal tissue (versus 23% in those cured), wherein CACNA1D mutations were most prevalent (63% versus 33% in those cured). In adjusted regression models, independent predictors of postoperative residual PA included Black versus White race (odds ratio, 5.10 [95% CI, 1.45–17.86]), AVS lateralization only at baseline (odds ratio, 8.93 [95% CI 3.00–26.32] versus both at baseline and after cosyntropin stimulation), and CT-AVS disagreement (odds ratio, 2.75 [95% CI, 1.20–6.31]). CONCLUSIONS: Multifocal, asymmetrical bilateral PA is relatively common, and it cannot be excluded by robust AVS lateralization. Long-term postoperative monitoring should be routinely pursued, to identify residual PA and afford timely initiation of targeted medical therapy.